Serum levels of apoptosis inhibitor of macrophage are associated with hepatic fibrosis in patients with chronic hepatitis C

BMC Gastroenterology

Hirohito Tsubouchi²  Susumu Eguchi¹  Masaaki Hidaka¹  Yuko Shimada⁴  Makoto Oketani³  Akihiro Moriuchi³  Tsutomu Tamai³  Kotaro Kumagai³  Kazuaki Tabu³  Kohei Oda³  Tsuyoshi Nosaki³  Yozo Yoshimine³  Akio Ido³  Seiichi Mawatari³  Hirofumi Uto³  Kumiko Mera³ 

[1] Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852–8501, Japan;Department of HGF Tissue Repair and Regenerative Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan;Digestive and Lifestyle Diseases, Department of Human and Environmental Sciences, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan;Miyazaki Prefectural Industrial Support Foundation, 16500-2 Higashikaminaka, Sadowara-cho, Miyazaki 880-0303, Japan

关键词: Insulin resistance;    Chronic hepatitis;    Hepatitis C virus;    Hepatic fibrosis;    Adipocytokine;    Apoptosis inhibitor of macrophage;   

Others  :  855721
DOI  :  10.1186/1471-230X-14-27

 received in 2013-10-16, accepted in 2014-02-05,  发布年份 2014

【 摘 要 】

Background

Apoptosis inhibitor of macrophage (AIM) and adipocytokines are involved in the metabolic syndrome, which has been putatively associated with the progression of chronic hepatitis C (CHC). However, the association between these cytokines and CHC is not fully elucidated. The aim of this study is to test whether serum levels of AIM and adipocytokines are associated with histological features, homeostasis model assessment-insulin resistance index (HOMA-IR), or whole body insulin sensitivity index (WBISI) in CHC patients.

Methods

Serum samples were obtained from 77 patients with biopsy-proven CHC. In 39 patients without overt diabetes mellitus, a 75 g oral glucose tolerance test (OGTT) was performed and HOMA-IR and WBISI were calculated.

Results

A serum AIM level of ≥1.2 μg/ml was independently associated with advanced hepatic fibrosis (F2 or F3) (odds ratio [OR], 5.612; 95% confidence interval [CI], 1.103–28.563; P = 0.038) based on a multivariate analysis, but there was no significant association between AIM and hepatic steatosis or inflammation. Furthermore, a serum leptin level of ≥8.6 ng/ml was independently associated with the presence of hepatic steatosis (≥5%) (OR, 6.195; 95% CI, 1.409–27.240; P = 0.016), but not hepatic fibrosis or inflammation. No relationship was observed between levels of adiponectin or resistin and hepatic histological parameters based on a multivariate analysis. Although serum levels of leptin, resistin, and adiponectin were significantly correlated with HOMA-IR and WBISI, there was no significant relationship between serum AIM levels and HOMA-IR or WBISI, respectively.

Conclusion

High serum levels of AIM in CHC patients are potentially related to advanced hepatic fibrosis. AIM and adipocytokines are possibly associated with pathological changes via a different mechanism.

【 授权许可】

   
2014 Mera et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Teoh NC, Farrell GC: Management of chronic hepatitis C virus infection: a new era of disease control. Intern Med J 2004, 34:324-337.
• [2]Hu KQ, Kyulo NL, Esrailian E, Thompson K, Chase R, Hillebrand DJ, Runyon BA: Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States. J Hepatol 2004, 40:147-154.
• [3]Hu KQ, Currie SL, Shen H, Cheung RC, Ho SB, Bini EJ, McCracken JD, Morgan T, Bräu N, Schmidt WN, Jeffers L, Wright TL, VA HCV-001 Study Group: Clinical implications of hepatic steatosis in patients with chronic hepatitis C: a multicenter study of U.S. veterans. Dig Dis Sci 2007, 52:570-578.
• [4]White DL, Ratziu V, El-Serag HB: Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol 2008, 49:831-844.
• [5]Cua IH, Hui JM, Kench JG, George J: Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C. Hepatology 2008, 48:723-731.
• [6]Moucari R, Asselah T, Cazals-Hatem D, Voitot H, Boyer N, Ripault MP, Sobesky R, Martinot-Peignoux M, Maylin S, Nicolas-Chanoine MH, Paradis V, Vidaud M, Valla D, Bedossa P, Marcellin P: Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008, 134:416-423.
• [7]Miyazaki T, Hirokami Y, Matsuhashi N, Takatsuka H, Naito M: Increased susceptibility of thymocytes to apotosis in mice lacking AIM, a novel murine macrophage-derived soluble factor belonging to the scavenger receptor cysteine-rich domain superfamily. J Exp Med 1999, 189:413-422.
• [8]Kurokawa J, Nagano H, Ohara O, Kubota N, Kadowaki T, Arai S, Miyazaki T: Apoptosis inhibitor of macrophage (AIM) is required for obesity-associated recruitment of inflammatory macrophages into adipose tissue. Proc Natl Acad Sce USA 2011, 108:12072-12077.
• [9]Miyazaki T, Kurokawa J, Arai S: AIMing at metabolic syndrome.-Towards the development of novel therapies for metabolic disease via apoptosis inhibitor of macrophage (AIM). Circ J 2011, 75:2522-2531.
• [10]Rabe K, Lehrke M, Parhofer KG, Broedl UC: Adipokines and insulin resistance. Mol Med 2008, 14:741-751.
• [11]Honda H, Ikejima K, Hirose M, Yoshikawa M, Lang T, Enomoto N, Kitamura T, Takei Y, Sato N: Leptin is required for fibrogenic responses induced by thioacetamid in the murine liver. Hepatology 2002, 36:12-21.
• [12]Handy JA, Fu PP, Kumar P, Mells JE, Sharma S, Saxene NK, Anania FA: Adiponectin inhibits leptin signaling via multiple mechanisms to exert protective effects against hepatic fibrosis. Biochem J 2011, 440:385-395.
• [13]Koerner A, Kratzsch J, Kiess W: Adipocytokines: leptin—the classical, resistin—the controversical, adiponectin—the promising, and more to come. Best Pract Res Clin Endocrinol Metab 2005, 19:525-546.
• [14]Tiftikci A, Atug O, Yilmaz Y, Eren F, Ozdemir FT, Yapali S, Ozdogan O, Celikel CA, Imeryuz N, Tozun N: Serum lebels of adipokines in patients with chronic HCV infection: relationship with steatosis and fibrosis. Arch Med Res 2009, 40:294-298.
• [15]Tsochatzis E, Papatheodoridis GV, Hadziyannis E, Georgiou A, Kafiri G, Tiniakos DG, Manesis EK, Archimandritis AJ: Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity. Scand J Gastroenterol 2008, 43:1128-1136.
• [16]Marra F, Bertolani C: Adipokines in liver diseases. Hepatology 2009, 50:957-969.
• [17]Bertolani C, Marra F: The role of adipokines in liver fibrosis. Pathophysiology 2008, 15:91-101.
• [18]Cua IH, Hui JM, Bandara P, Kench JG, Farrell GC, McCaughan GW, George J: Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology 2007, 46:66-73.
• [19]Matsuda M, DeFronzo RA: Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999, 22:1462-1470.
• [20]Matsumoto K, Yoshimoto J, Sugo H, Kojima K, Futagawa S, Matsumoto T: Relationship between the histological degrees of hepatitis and the postoperative recurrence of hepatocellular carcinoma in patients with hepatitis C. Hepatol Res 2002, 23:196-201.
• [21]Leandro G, Mangia A, Hui J, Fabris P, Rubbia-Brandt L, Colloredo G, Adinolfi LE, Asselah T, Jonsson JR, Smedile A, Terrault N, Pazienza V, Giordani MT, Giostra E, Sonzogni A, Ruggiero G, Marcellin P, Powell EE, George J, Negro F, HCV Meta-Analysis (on) Individual Patients' Data Study Group: Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006, 130:1636-1642.
• [22]Gangadharan B, Antrobus R, Dwek RA, Zitzmann N: Novel serum biomarker candidates for liver fibrosis in hepatitis C patients. Clin Chem 2007, 53:1792-1799.
• [23]Gray J, Chattopadhyay D, Beale GS, Patman GL, Miele L, King BP, Stewart S, Hudson M, Day CP, Manas DM, Reeves HL: A proteomic strategy to identify novel serum biomarkers for liver cirrhosis and hepatocellular cancer in individuals with fatty liver disease. BMC Cancer 2009, 9:271. BioMed Central Full Text
• [24]Iwamura Y, Mori M, Nakashima K, Mikami T, Murayama K, Arai S, Miyazaki T: Apoptosis inhibitor of macrophage (AIM) diminishes lipid droplet-coating proteins leading to lipolysis in adipocytes. Biochem Biophys Res Commun 2012, 422:476-481.
• [25]Haruta I, Kato Y, Hashimoto E, Minjares C, Kennedy S, Uto H, Yamauchi K, Kobayashi M, Yusa S, Müller U, Hayashi N, Miyazaki T: Association of AIM, a novel apoptosis inhibitory factor, with hepatitis via supporting macrophage survival and enhancing phagocytotic function of macrophages. J Biol Chem 2001, 276:22910-22914.
• [26]Dolganiuc A, Norkina O, Kodys K, Catalano D, Bakis G, Marshall C, Mandrekar P, Szabo G: Viral and host factors induce macrophage activation and loss of toll-like receptor tolerance in chronic HCV infection. Gastroenterology 2007, 133:1627-1636.
• [27]Brunt EM: Nonalcoholic steatohepatitis: definition and pathology. Semin liver Dis 2001, 21:3-16.
• [28]Novo E, Marra F, Zamara E, Valfrè Di Bonzo L, Monitillo L, Cannito S, Petrai I, Mazzocca A, Bonacchi A, De Franco RS, Colombatto S, Autelli R, Pinzani M, Parola M: Overexpression of Bcl-2 by activated human hepatic stellate cells: resistance to apoptosis as a mechanism of progressive hepatic fibrogenesis in humans. Gut 2006, 55:1174-1182.
• [29]Hui JM, Sud A, Farrell GC, Bandara P, Byth K, Kench JG, McCaughan GW, George J: Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology 2003, 125:1695-1704.
• [30]Muzzi A, Leandro G, Rubbia Brandt L, James R, Keiser O, Malinverni R, Dufour JF, Helbling B, Hadengue A, Gonvers JJ, Müllhaupt B, Cerny A, Mondelli MU, Negro F, Swiss Hepatitis C Cohort Study: Inrulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients. J Hepatol 2005, 42:41-46.
• [31]Baig NA, Herrine SK, Rubin R: Liver disease and diabetes mellitus. Clin Lab Med 2001, 21:193-207.
• [32]Svegliati-Baroni G, Ridolfi F, Di Sario A, Casini A, Marucci L, Gaggiotti G, Orlandoni P, Macarri G, Perego L, Benedetti A, Folli F: Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways. Hepatology 1999, 29:1743-1751.
• [33]Paradis V, Perlemuter G, Bonvoust F, Dargere D, Parfait B, Vidaud M, Conti M, Huet S, Ba N, Buffet C, Bedossa P: High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001, 34:738-744.
• [34]Borai A, Livingstone C, Kaddam I, Ferns G: Selection of the appropriate method for the assessment of insulin resistance. BMC Med Res Methodol 2011, 11:158. BioMed Central Full Text
• [35]Romero-Gómez M, Castellano-Megias VM, Grande L, Irles JA, Cruz M, Nogales MC, Alcón JC, Robles A: Serum leptin levels correlate with hepatic steatosis in chronic hepatitis C. Am J Gastroenterol 2003, 98:1135-1141.
• [36]Piche T, Vandenbos F, Abakar-Mahamat A, Vanbiervliet G, Barjoan EM, Calle G, Giudicelli J, Ferrua B, Laffont C, Benzaken S, Tran A: The severity of liver fibrosis is associated with high leptin levels in chronic hepatitis C. J Viral Hepat 2004, 11:91-96.
• [37]Jonsson JR, Moschen AR, Hickman IJ, Richardson MM, Kaser S, Clouston AD, Powell EE, Tilg H: Adiponectin and its receptors in patients with chronic hepatitis C. J Hepatol 2005, 43:929-936.
• [38]Liu CJ, Chen PJ, Jeng YM, Huang WL, Yang WS, Lai MY, Kao JH, Chen DS: Serum adiponectin correlates with viral characteristics but not histologic features in patients with chronic hepatitis C. J Hepatol 2005, 43:235-242.
• [39]Fartoux L, Chazouillères O, Wendum D, Poupon R, Serfaty L: Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. Hepatology 2005, 41:82-87.
• [40]Itoh Y, Nishimura T, Yamaguchi K, Yokomizo C, Fujii H, Minami M, Nagao Y, Sumida Y, Hashimoto H, Umemura A, Shima T, Okanoue T, Yoshikawa T: Hepatic steatosis in chronic hepatitis C patients infected with genotype 2 is associated with insulin resistance, hepatic fibrosis and affects cumulative positivity of serum hepatitis C virus RNA in peginterferon and ribavirin combination therapy. Hepatol Res 2011, 41:1145-1152.
• [41]Ohnishi M, Tsuge M, Kohno T, Zhang Y, Abe H, Hyogo H, Kimura Y, Miki D, Hiraga N, Imamura M, Takahashi S, Ochi H, Hayes CN, Tanaka S, Arihiro K, Chayama K: IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients. J Gastroenterol 2012, 47:834-844.